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Abstract: The accuracy of a novel community health worker anti-
retroviral therapy eligibility assessment tool was examined in
community members in Blantyre, Malawi. Nurses independently
performed World Health Organization (WHO) staging and CD4
counts. One hundred ten (55.6%) of 198 HIV-positive participants
had a CD4 count of ,350 cells per cubic millimeter. The community
health worker tool signiﬁcantly outperformed WHO clinical staging in
identifying CD4 count of ,350 cells per cubic millimeter in terms of
sensitivity (41% vs. 19%), positive predictive value (75% vs. 68%),
negative predictive values (53% vs. 47%), and area under the receiver–
operator curve (0.62 vs. 0.54; P = 0.017). Reliance on WHO staging is
likely to result in missed and delayed antiretroviral therapy initiation.
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INTRODUCTION
The 2010 World Health Organization (WHO) guide-
lines recommend that HIV-infected adults with a CD4 count
of ,350 cells per cubic millimeter be initiated onto antiretro-
viral therapy (ART).1 Availability of CD4 count measurement
remains low in much of sub-Saharan Africa. For example, in
Malawi, only 12% of HIV care facilities have functional
on-site capacity for CD4 count measurement.2 Where facili-
ties for CD4 count are not available, individuals assessed, as
being in WHO clinical stage 3 or 4, should receive ART.1
The WHO clinical staging system for HIV was
introduced in 19903 and was based on previous highly spe-
ciﬁc WHO case deﬁnitions for AIDS that were used in the era
before the availability of reliable and rapid HIV diagnostic
tests.4,5 Although the WHO clinical staging system has good
prognostic value in predicting death6 and response to ART,7 it
was not originally designed to be used for as screening tool
for ART eligibility. Previous studies8–11 have shown the sen-
sitivity of nurse-performed WHO stage 3 or 4 assessment in
identifying CD4 count of ,350 cells per cubic millimeter to
be low (between 18% and 65%), potentially resulting in
missed and delayed ART initiation.12
We previously found that eligibility assessments
were a frequent cause of dropout before ART initiation,13
with health workers ﬁnding WHO staging overly complex
and time consuming, and individuals reporting that com-
pletion of CD4 count measurement required multiple fa-
cility visits.14,15 With task shifting of HIV testing to
community health workers (CHWs)16 and moves toward
“test-and-treat,”17 eligibility assessments should be com-
pleted immediately following HIV diagnosis to maximize
opportunities for linkage to ART. We therefore developed
a brief CHW tool for assessing ART eligibility and com-
pared its accuracy with that of with the current WHO clin-
ical staging system.
METHODS
Study Design
An accuracy study nested within a cluster-randomized
trial that was investigating community-based approaches to
HIV diagnosis and treatment.18
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ART Eligibility Guidelines and Development
of Novel ART Eligibility Screening Tool
National ART eligibility guidelines in Malawi matched
WHO recommendations (ie, CD4 count of ,350 cells/mm3
or in WHO stage 3 or 4).1,19
The CHW tool was designed based on the WHO “Ask,
Look, Classify, Act” approach incorporated within guidelines
for the Integrated Management of Adult and Adolescent Ill-
ness.20 Questions were constructed for inclusion in the CHW
tool from existing components of the WHO clinical staging
system21; with additional validated questions that have pre-
viously assessed to be important predictors of ART eligibility
(self-rated general health14,22) and advanced immunosuppres-
sion (self-rated skin or hair change).23–25 All questions
included had to be easily understood and performed by
CHWs and not require further laboratory investigations. The
CHW tool classiﬁes HIV-positive patients into 2 groups:
those who are ART eligible (analogous to WHO stage 3 or
4) and those who are not ART eligible (analogous to WHO
stage 1 or 2). Individuals who responded positively to any of
the following items were classiﬁed as ART eligible:
• reports fever or weight loss or diarrhea for all of last
month,21
• enough weight loss to affect ﬁt of clothing,21
• sore mouth or swallowing,21
• treated for TB or any other infection (excluding malaria and
“ﬂu”) in the last year,21
• self-rated change in skin or hair,23–25
• unable to carry out daily duties (work, go to school, do
housework),21 and
• self-rated general health poor or fair,14
Study Site and Population
Adult ($16 years) residents of 3 high-density urban
townships in the north west of Blantyre, Malawi, were pro-
vided with access to home HIV self-testing through CHWs.
CHWs were adult residents selected by a participatory
approach and who received training in HIV testing and coun-
seling (HTC). CHWs performed the novel ART eligibility
assessment tool for individuals who disclosed a positive
self-test result. HIV-positive individuals received a home visit
from a nurse who independently performed conﬁrmatory
HTC, TB screening (symptom screen and sputum collection
for smear and culture if positive), WHO clinical staging
(without reference to the result of the CHW tool assessment),
and drew blood for CD4 count. ART eligible participants (on
national criteria) received offer of home or facility ART ini-
tiation and noneligible participants were referred to pre-ART
clinics at local health centers.
Laboratory Methods
Blood samples were analyzed using the Partec Cyﬂow
SL-3 platform (Partec, Görlitz, Germany).
Statistical Methods
Sensitivity, speciﬁcity, positive predictive value (PPV),
and negative predictive value (NPV) were calculated for both
the CHW tool and WHO clinical staging using CD4 count
of ,350 cells per cubic millimeter as the referent. As WHO
has recently proposed expanding ART eligibility to include
individuals with CD4 count of ,500 cells per cubic millime-
ter,3,26 we repeated analysis with this criteria as the referent. A
sample size of 191 patients was required to estimate sensitiv-
ity and speciﬁcity with a precision of 610% at the P = 0.05
level.27 Statistical analysis was done using Stata 12.1
(Statacorp, College Station, TX).
Ethical Approval
The research ethics committees of the College of
Medicine of Malawi, Liverpool School of Tropical Medicine,
and London School of Hygiene and Tropical Medicine
granted ethical approval for the parent cluster-randomized
trial. All participants gave written informed consent to
participate or witnessed thumbprint consent if illiterate.
RESULTS
Baseline Characteristics
Between February and November 2012, 198 of 206
HIV-positive adult community members were recruited to the
study (96.1% participation). Men comprised 42% (84/198) of
participants and were younger, had a higher level of
schooling, and were more likely to have salaried employment
than women (Table 1).
Outcomes of ART Eligibility Assessments
A total of 31 of 198 (15.6%) individuals were assessed
to be in WHO stage 3 or 4 by nurses, with men signiﬁcantly
more likely to be in the more advanced WHO stage 3 or 4
than women [19/84 (22.6%) vs. 12/114 (10.5%) respectively;
P = 0.021]. Men also had a signiﬁcantly lower median CD4
count at assessment compared with women [262 cells/mm3
(interquartile range, IQR: 148–373) vs. 374 cells/mm3 (IQR:
195–512); P = 0.002]. A total of 110 of 198 (55.6%) partic-
ipants had a CD4 count below the Malawian national ART
eligibility threshold of ,350 cells per cubic millimeter.
Performance of CHW Tool in Identifying CD4
count of\350 Cells per Cubic Millimeter
One participant did not have the CHW tool completed
by the CHW, leaving 197 participants who were analyzed
with complete data for outcome of CHW tool, CD4 count,
and WHO clinical staging assessment.
The sensitivity of the CHW tool (41.3%; 95% CI:
31.9% to 51.1%) was substantially higher than that of
nurse-performed WHO clinical stage 3 or 4 assessment
(19.1%, 95% CI: 12.2% to 27.7%) in identifying CD4
count of ,350 cells per cubic millimeter (Table 2). The
speciﬁcity of the CHW tool was 83.0% (95% CI: 73.4% to
90.1%) compared with 88.6% (95% CI: 80.1% to 94.4%)
for WHO clinical stage 3 or 4 assessment. The area under
the curve (AUC) was signiﬁcantly higher for the CHW
tool (0.62; 95% CI: 0.56 to 0.68) compared with WHO
clinical stage 3 or 4 assessment (0.54; 95% CI: 0.49 to
0.59; P = 0.017).
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Unexpectedly, there were differences in test perfor-
mance when results were stratiﬁed by gender. The sensitiv-
ity and speciﬁcity of the CHW tool were higher among men
(45.6% and 92.3%, respectively) than among women
(36.5% and 79.0%, respectively). For both men and women,
however, the PPV (92.9% vs. 78.9% and 59.4% vs. 50.0%,
respectively) and NPV (43.6% vs. 33.8% and 59.8% vs.
54.9%, respectively) of the CHW tool was higher than that
of WHO clinical staging. The largest AUC was observed for
men identiﬁed as ART eligible by the CHW tool (AUC =
0.69), which was signiﬁcantly higher than for WHO stage 3
or 4 assessed men (AUC = 0.55; P = 0.016). For women,
although the AUC for the CHW tool (AUC = 0.58) was
greater than for WHO stage 3 or 4 assessment (AUC =
0.51), the difference was relatively small and did not reach
statistical signiﬁcance (P = 0.104).
Using CD4 count of ,500 cells per cubic millimeter as
the referent, the CHW tool similarly outperformed WHO
clinical staging assessment in terms of sensitivity, PPV,
NPV, and AUC (Table 2), although performance of both tools
was worse than at the CD4 count of ,350 cell per cubic
millimeter cutoff.
DISCUSSION
The main ﬁnding from this study was that our brief
CHW tool signiﬁcantly outperformed the current WHO
clinical staging system for identifying ART eligible indi-
viduals with CD4 count of ,350 cells per cubic millimeter.
The ease with which we were able to improve on the current
WHO staging system emphasizes the need for improved
tools that can be used by community and facility-based
health workers to ensure “same-day, same-site” eligibility
assessments and prompt linkage to ART. Moreover, the low
sensitivity and high risk of misclassiﬁcation when using the
standard WHO clinical staging system in this and other
studies8–11 questions its appropriateness as an ART eligibil-
ity assessment tool, especially with increasing CD4 count
thresholds.28
The CHW tool was found to be signiﬁcantly more
accurate than WHO clinical staging assessment in terms of
sensitivity, PPV, and NPV. In contrast to the WHO clinical
staging system, which, strictly followed, requires nurses or
doctors to undertake a complex and time-consuming assess-
ment,14 our CHW tool was easily performed in the commu-
nity and could be used in settings without sophisticated
laboratories. The poor performance of nurse WHO clinical
staging system in this and other studies8–11 is therefore not
a factor of the capability of nurses. Instead it is a reﬂection of
the inherent limitations of the WHO screening tool for iden-
tifying ART eligibility, a task for which it was never origi-
nally intended.
The CD4 count is the gold standard for determining
ART eligibility, but access to laboratory measurement is
problematic in most resource-limited settings.29 Point of care
CD4 count measurement has the potential to negate some of
these issues and improve retention in pre-ART care,30 but it
is not yet widely available. Where CD4 count is not avail-
able at the point of HIV diagnosis, improved eligibility
assessment tools such as ours could allow an immediate
decision on ART initiation to be made, facilitating “test-
and-treat” delivery of ART.
The accuracy of the CHW tool was noted to be higher
among men than women. This may reﬂect the relatively more
advanced immunosuppression of men compared with women
TABLE 1. Characteristics of Study Participants
Men Women P*
Total 84 114
Age, yrs (mean, SD) 37 8.6 31 8.3 ,0.001
Pregnant (if female) n/a 2 1.8%
Breastfeeding (if female) n/a 19 16.7%
Body mass index, kg/m2
(mean, SD)
20 2.8 22 4.1 ,0.001
Marital status
Married/cohabiting 61 72.6% 73 64.0% 0.023
Never married 9 10.7% 5 4.4%
Widowed/separated/
divorced
14 16.7% 36 31.6%
Ever lost a spouse to death 16 19.3% 26 22.8% 0.569
Able to read a one page letter
or newspaper
78 94.0% 97 85.8% 0.069
Receives a regular salaried
income
31 40.3% 8 8.2% ,0.001
Highest level of education
No schooling 3 3.6% 1 0.9% 0.042
Primary 39 46.4% 75 65.8%
Secondary 40 47.6% 36 31.6%
Higher 2 2.4% 2 1.8%
Ever previously tested for HIV 46 56.1% 85 75.9% 0.004
Tested for HIV in preceding 12
months
12 14.5% 24 22.2% 0.174
Ever previously tested HIV
positive
20 23.8% 39 34.5% 0.105
Tested as a couple 25 29.8% 28 24.6% 0.414
Self-rated general health
Excellent 8 9.5% 10 8.8% 0.556
Good 51 60.7% 75 66.4%
Fair 22 26.2% 27 23.9%
Poor 3 3.6% 1 0.9%
WHO clinical stage
Stage 1 or 2 65 77.4% 102 89.5% 0.021
Stage 3 or 4 19 22.6% 12 10.5%
CD4 count, cells/mm3
(median, IQR)
262 148–373 374 195–512 0.002
CD4 count group, cells/mm3
$500 11 13.1% 30 26.3% 0.015
$350 to ,500 15 17.9% 32 28.1%
$200 to ,350 27 32.1% 23 20.2%
$50 to ,200 30 35.7% 26 22.8%
,50 1 1.2% 3 2.6%
CHW ART eligibility assessment tool
ART eligible 1128 33.7% 32 28.1% 0.394
Not ART eligible 55 66.3% 82 71.9%
* The x2 test for categorical data, t test for comparison of means, and the rank sum
test for comparison of medians.
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in the study, consistent with ﬁndings from HIV care
programmes in sub-Saharan Africa showing that men initiate
ART later than women.28 Women may have also been less
likely to report symptoms included in the tool. Future, larger
studies should examine the performance of CHWs tool
among men and women across CD4 count strata.
Our CHW tool was designed pragmatically to combine
ease of use by CHWs with questions that were hoped would
have a high discriminatory power. Component parts of the
tool were not captured and so we were unable to assess the
contribution of individual items to the tool performance. As
such, it is possible that the number of items could be reduced,
or the sensitivity and speciﬁcity improved beyond that
reported here. Future research should attempt to reﬁne the
tool by examining the contribution of the included items to
the test performance and evaluating any modiﬁcations.
In conclusion, this study has shown that a novel
screening tool performed by CHWs can distinguish ART
eligible from ART ineligible HIV-positive individuals. This
could be added to HTC counselors’ posttest evaluations, al-
lowing same-day, same-site HIV diagnosis and ART eligibil-
ity assessment. The accuracy of the CHW tool signiﬁcantly
outperformed WHO staging by a nurse and the ease with
which we were able to improve on the current WHO clinical
staging system shows the urgent need for improved ART
eligibility assessment tools.
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